The REPEAT Trial: Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma, a Phase 1b Study

Trial Profile

The REPEAT Trial: Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma, a Phase 1b Study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Regorafenib (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Acronyms REPEAT
  • Most Recent Events

    • 26 Jul 2016 Planned End Date changed from 1 Apr 2018 to 1 Mar 2018.
    • 26 Jul 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.
    • 26 Jul 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top